Enhertu (Trastuzumab Deruxtecan)
Brand Name: EnhertuActive Ingredient: Trastuzumab Deruxtecan
Dosage Form: 100mg/vial
Manufacturer Name: Daiichi Sankyo
Why is Enhertu prescribed?
Enhertu can only be used if it has been determined that the cancer “overexpressed HER2,” which means it overproduced the HER2 protein on the tumor cells’ surface, speeding up the tumor cells’ rate of multiplication. Enhertu is the only medication used to treat patients with two or more HER2-targeted treatments.
Due to the possibility of allergic responses, the patient should be monitored both during and after the infusion for symptoms including fever and chills. The doctor may reduce the dosage or temporarily or completely cease the medication if the patient has side effects.
Until the condition worsens or there is intolerable toxicity, Enhertu must be given as a 5.4 mg/kg IV infusion once every three weeks (on a 21-day cycle). Get Enhertu injection at the best price in UAE from us, HAYAT ALHIKMAH, through Name patient Import Services or Govt Hospital Supply.
Who should not take Enhertu?
- Individuals with allergies to any component of Enhertu
- A complete list of Enhertu's ingredients can be seen at the end of the patient information sheet.
- Women who are pregnant or breastfeeding.
If you’re unsure, speak with your doctor.
What are the possible side effects of Enhertu?
Severe possible side effects of Enhertu include:
- Nausea
- Low white blood cell counts
- Low red blood cell counts
- Increased liver function tests
- Feeling tired
- Vomiting
- Hair loss
- Constipation
- Low levels of blood potassium
- Decreased appetite
- Diarrhea
- Pain in muscles and bones
- Infections of the respiratory tract
- Headache
- Stomach area (abdominal) pain
Special Precautions For Kineret
- Enhertu is sold in single dose vials at a reasonable injection price.
- Checking the vial labels to confirm that the medication being prepared and delivered is Enhertu (trastuzumab deruxtecan) rather than trastuzumab or trastuzumab emtansine is crucial to preventing medication errors.
- Enhertu is a sterile, unpreserved fluid.
- Enhertu is administered intravenously. It needs to be reconstituted and diluted by a medical professional before being given as an intravenous infusion.
- Enhertu shouldn't be administered through boluses or pushes into the vein.
- In the reconstituted solution, look for particles and discolouration.
- The combination must be transparent and colorless to a pale yellow hue.
- Do not use it, if the solution appears to be discolored, to have visible particles, or to be foggy.
- The reconstituted Enhertu vials should be stored for up to 24 hours in the refrigerator, away from light, at a temperature between 2 and 8 degrees Celsius. Prevent freezing.
- Keep in the refrigerator at 2 to 8 degrees Celsius.
- Avoid freezing.
- To protect against light, keep it in the original container.
- The vial shouldn't be shaken.
- For ambulatory use, Enhertu may be left out of the fridge for up to 12 hours at a temperature no higher than 25 °C without going past the expiration date.
- The product must be thrown off once this time has passed instead of returning it to the refrigerator.
- Following local legislation, waste and unneeded pharmaceuticals should be disposed of.
About Us
We are a leading pharmaceutical wholesaler, HAYAT ALHIKMAH, situated in Dubai. By providing generic medications, reference-listed drugs, name patient import services, and temperature-controlled products simple to access for our consumers, we help them overcome geographic distances.
We offer affordable access to enhertu injection in Dubai with ease and speed. Depending on the customer’s needs, we provide a quality guarantee and shipping anywhere in the world.
Please schedule a consultation with us by calling us at +971 54 777 1238 or email us at [email protected] to know how much enhertu injection costs in Dubai. Our helpful team would be happy to assist you and provide any general or medical information.
Distributors
Ware House
Awards
FAQ's
Breast cancer that is metastatic or cannot be removed through surgery is treated with Enhertu. It can only be used if it has been established that the tumor overexpresses HER2, a term for cancer producing a lot of the protein HER2 on the surface of the tumor cells, causing the tumor cells to multiply quickly. When a patient has had two or more HER2-targeted therapies, Enhertu is administered independently. Trastuzumab Deruxtecan is the medication’s active ingredient.
- The metastatic environment
- Have experienced a disease recurrence during treatment or within six months of finishing it, whether in the neoadjuvant or adjuvant context.
Only a prescription is needed to buy Enhertu. It needs to be prescribed by a physician and administered under the guidance of a medical expert with knowledge of cancer medications. Once every three weeks, it is infused into a vein for over 90 minutes. If the patient tolerates the 90-minute initial infusion, they can get additional infusions over 30 minutes. As long as the medication is still working, treatment may be continued. The weight of the patient affects the dose. Due to the possibility of allergic responses, the patient should be watched during and after the infusion for symptoms, including fever and chills. The doctor may lower the dose or temporarily or entirely cease the medication if the patient has side effects.
It is recommended to treat adult patients with metastatic or unresectable HER2-positive breast cancer who have previously undergone an anti-HER2-based regimen to use ENHERTU, a HER2-directed antibody, and a topoisomerase inhibitor combination. Enhertu successfully reduced tumor size in patients with metastatic breast cancer or breast cancer resistant to surgical resection, according to a current primary trial. All of the patients had undergone at least two HER2-based therapies. Does it need to provide any light protection? Avoid freezing. There is no preservative in ENHERTU. Upon reconstitution, If not used right away, keep the reconstituted ENHERTU vials in the fridge for up to 24 hours at 2°C to 8°C (36°F to 46°F) while keeping them away from light.
Trastuzumab deruxtecan is the active ingredient of Enhertu. It is composed of two linked active ingredients, such as HER2 is present in significant amounts on some cancer cells and is targeted by the protein known as trastuzumab, a monoclonal antibody. Trastuzumab binds to HER2, stimulating immune system cells to attack cancer cells. Deruxtecan inhibits topoisomerase I, an enzyme involved in copying cell DNA, which is necessary for producing new cells. Cancer cells are finally killed because the enzyme is blocked, which stops the growth of the cells. How long does Enhertu last in your body? Females capable of getting pregnant should utilise reliable contraception during their ENHERTU treatment and for seven months following the final dose.
Enhertu can only be used if it has been determined that the cancer “overexpressed HER2,” which means it overproduced the HER2 protein on the tumor cells’ surface, speeding up the tumor cells’ rate of multiplication. Enhertu is the only medication used to treat patients with two or more HER2-targeted treatments.
Due to the possibility of allergic responses, the patient should be monitored both during and after the infusion for symptoms including fever and chills. The doctor may reduce the dosage or temporarily or completely cease the medication if the patient has side effects.
Until the condition worsens or there is intolerable toxicity, Enhertu must be given as a 5.4 mg/kg IV infusion once every three weeks (on a 21-day cycle). Get Enhertu injection at the best price in UAE from us, HAYAT ALHIKMAH, through Name patient Import Services or Govt Hospital Supply.
- Individuals with allergies to any component of Enhertu
- A complete list of Enhertu’s ingredients can be seen at the end of the patient information sheet.
- Women who are pregnant or breastfeeding.
Severe possible side effects of Enhertu include:
- Nausea
- Low white blood cell counts
- Low red blood cell counts
- Increased liver function tests
- Feeling tired
- Vomiting
- Hair loss
- Constipation
- Low levels of blood potassium
- Decreased appetite
- Diarrhea
- Pain in muscles and bones
- Infections of the respiratory tract
- Headache
- Stomach area (abdominal) pain
- Enhertu is sold in single dose vials at a reasonable injection price.
- Checking the vial labels to confirm that the medication being prepared and delivered is Enhertu (trastuzumab deruxtecan) rather than trastuzumab or trastuzumab emtansine is crucial to preventing medication errors.
- Enhertu is a sterile, unpreserved fluid.
- Enhertu is administered intravenously. It needs to be reconstituted and diluted by a medical professional before being given as an intravenous infusion.
- Enhertu shouldn’t be administered through boluses or pushes into the vein.
- In the reconstituted solution, look for particles and discolouration.
- The combination must be transparent and colorless to a pale yellow hue.
- Do not use it, if the solution appears to be discolored, to have visible particles, or to be foggy.
- The reconstituted Enhertu vials should be stored for up to 24 hours in the refrigerator, away from light, at a temperature between 2 and 8 degrees Celsius. Prevent freezing.
- Keep in the refrigerator at 2 to 8 degrees Celsius.
- Avoid freezing.
- To protect against light, keep it in the original container.
- The vial shouldn’t be shaken.
- For ambulatory use, Enhertu may be left out of the fridge for up to 12 hours at a temperature no higher than 25 °C without going past the expiration date.
- The product must be thrown off once this time has passed instead of returning it to the refrigerator.
- Following local legislation, waste and unneeded pharmaceuticals should be disposed of.
